SOBI acquires all rights to Kineret
Swedish Orphan Biovitrum AB (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen for all therapeutic indications. The revised agreement builds on the previous agreement that gave Sobi rights for Kineret within the field of Rheumatoid arthritis (RA) and four orphan drug indications, including Cryopyrin Associated Periodic Syndrome (CAPS).
Sobi also acquired the right to additional data for Kepivance allowing the company to explore a potential new therapeutic indication based on two completed phase III trials performed by Amgen. The two randomized double blind placebo controlled trials, involving over 400 patients, demonstrate the potential for Kepivance to reduce the incidence of severe oral mucositis in patients undergoing treatment for advanced head and neck cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins